Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab

References

• Prieto-PérezRCabaleiroTDaudénEOchoaDRomanMAbad-SantosFGenetics of Psoriasis and Pharmacogenetics of Biological DrugsAutoimmune Dis2013201361308624069534
   PubMedGoogle Scholar
• GriffithsCEBarkerJNPathogenesis and clinical features of psoriasisLancet2007370958326327117658397
   PubMed Web of Science ®Google Scholar
• ParisiRSymmonsDPGriffithsCEAshcroftDMIdentification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol2013133237738523014338
   PubMed Web of Science ®Google Scholar
• ChaoWHongzhongJEpidemiology of psoriasis: an updateInt J Dermatol Venereol201339297100
   Google Scholar
• DingXWangTShenYPrevalence of psoriasis in China: an epidemiological survey in six provincesChin J Derm Venereol2010247598612
   Google Scholar
• MeijiaoLIPengWMinCAIPrevalence and risk factors of psoriasis in Hainan province: an epidemiological surveyChin J Dermatol2013463157159
   Google Scholar
• GuangdePJinfengDYingHAn epidemiological survey of psoriasis in Jiaozuo city of Henan provinceJ Clin Dermatol2011403150151
   Google Scholar
• TsaiTFWangTSHungSTEpidemiology and comorbidities of psoriasis patients in a national database in TaiwanJ Dermatol Sci2011631404621543188
   PubMed Web of Science ®Google Scholar
• ChristophersEPsoriasis – epidemiology and clinical spectrumClin Exp Dermatol200126431432011422182
   PubMed Web of Science ®Google Scholar
• FarleyEMenterAPsoriasis: comorbidities and associationsG Ital Dermatol Venereol2011146191521317853
   PubMed Web of Science ®Google Scholar
• GladmanDDAntoniCMeasePCleggDONashPPsoriatic arthritis: epidemiology, clinical features, course, and outcomeAnn Rheum Dis200564Suppl 2ii14ii1715708927
   PubMed Web of Science ®Google Scholar
• TamLSLeungYYLiEKPsoriatic arthritis in AsiaRheumatology (Oxford)200948121473147719713440
   PubMed Web of Science ®Google Scholar
• FredrikssonTPetterssonUSevere psoriasis-oral therapy with a new retinoidDermatologica19781574238244357213
   PubMedGoogle Scholar
• YangQQuLTianHPrevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasisJ Eur Acad Dermatol Venereol201125121409141421349114
   PubMed Web of Science ®Google Scholar
• ZhizhongZJieFXueqinYChinese guidelines for treatment of psoriasisChin J Dermatol2009423213214
   Google Scholar
• HsuSPappKALebwohlMGConsensus guidelines for the management of plaque psoriasisArch Dermatol201214819510222250239
   PubMedGoogle Scholar
• PathiranaDOrmerodADSaiagPEuropean S3-guidelines on the systemic treatment of psoriasis vulgarisJ Eur Acad Dermatol Venereol200923Suppl 217019712190
   PubMed Web of Science ®Google Scholar
• MansouriBPatelMMenterABiological therapies for psoriasisExpert Opin Biol Ther201313121715173024160990
   PubMed Web of Science ®Google Scholar
• JunGXinZThe advances in the immune mechanism of psoriasis and treatment of biological agentsJ Dermatology and Venereology2013355260261
   Google Scholar
• CingozOUstekinumabMAbs20091321622120069753
   PubMed Web of Science ®Google Scholar
• NickoloffBJNestleFORecent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunitiesJ Clin Invest2004113121664167515199399
   PubMed Web of Science ®Google Scholar
• PereraGKDi MeglioPNestleFOPsoriasisAnnu Rev Pathol2012738542222054142
   PubMed Web of Science ®Google Scholar
• YawalkarNKarlenSHungerRBrandCUBraathenLRExpression of interleukin-12 is increased in psoriatic skinJ Invest Dermatol19981116105310579856816
   PubMed Web of Science ®Google Scholar
• HongKChuALúdvíkssonBRBergELEhrhardtROIL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorderJ Immunol1999162127480749110358203
   PubMed Web of Science ®Google Scholar
• QuatresoozPHermanns-LêTPiérardGEHumbertPDelvennePPiérard-FranchimontCUstekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primerJ Biomed Biotechnol2012201214741322754278
   PubMedGoogle Scholar
• KurzejaMRudnickaLOlszewskaMNew interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumabAm J Clin Dermatol201112211312521348542
   PubMed Web of Science ®Google Scholar
• LeeETrepicchioWLOestreicherJLIncreased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgarisJ Exp Med2004199112513014707118
   PubMed Web of Science ®Google Scholar
• BensonJMPerittDScallonBJDiscovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disordersMAbs20113653554522123062
   PubMed Web of Science ®Google Scholar
• ChandranVThe genetics of psoriasis and psoriatic arthritisClin Rev Allerg y Immunol2013442149156
   PubMed Web of Science ®Google Scholar
• CargillMSchrodiSJChangMA large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genesAm J Hum Genet200780227329017236132
   PubMed Web of Science ®Google Scholar
• CabaleiroTRománMGalloEAssociation between psoriasis and polymorphisms in the TNF, IL12B, and IL23R genes in Spanish patientsEur J Dermatol201323564064524135300
   PubMed Web of Science ®Google Scholar
• OkaAMabuchiTIkedaSIL12B and IL23R gene SNPs in Japanese psoriasisImmunogenetics2013651182382823955419
   PubMed Web of Science ®Google Scholar
• CaponFDi MeglioPSzaubJSequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisHum Genet2007122220120617587057
   PubMed Web of Science ®Google Scholar
• PreskyDHYangHMinettiLJA functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunitsProc Natl Acad Sci USA1996932414002140078943050
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet200837196251665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet200837196251675168418486740
   PubMed Web of Science ®Google Scholar
• RobinsonAKardosMKimballABPhysician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasisJ Am Acad Dermatol201266336937522041254
   PubMed Web of Science ®Google Scholar
• FarhiDUstekinumab for the treatment of psoriasis: review of three multicenter clinical trialsDrugs Today (Barc)201046425926420502723
   PubMed Web of Science ®Google Scholar
• GriffithsCEStroberBEvan de KerkhofPComparison of ustekinumab and etanercept for moderate-to-severe psoriasisN Engl J Med2010362211812820071701
   PubMed Web of Science ®Google Scholar
• Galván-BanqueriMMarín GilRSantos RamosBBautista PalomaFJBiological treatments for moderate-to-severe psoriasis: indirect comparisonJ Clin Pharm Ther201338212113023442134
   PubMed Web of Science ®Google Scholar
• FinlayAYKhanGKDermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp DermatolMay1994193210216
   Google Scholar
• TsaiTFHoJCSongMEfficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)J Dermatol Sci201163315416321741220
   PubMed Web of Science ®Google Scholar
• WoffordJMenterAUstekinumab for the treatment of psoriatic arthritisExpert Rev Clin Immunol201410218920224410536
   PubMed Web of Science ®Google Scholar
• GottliebAMenterAMendelsohnAUstekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialLancet2009373966463364019217154
   PubMed Web of Science ®Google Scholar
• McInnesIBKavanaughAGottliebABEfficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialLancet2013382989478078923769296
   PubMed Web of Science ®Google Scholar
• LiangXBiSYangWEpidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccinationVaccine2009276550655719729084
   PubMed Web of Science ®Google Scholar
• AbramsonAMenterAPerrilloRPsoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for managementJ Am Acad Dermatol20126761349136122727462
   PubMed Web of Science ®Google Scholar
• MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol200858582685018423260
   PubMed Web of Science ®Google Scholar
• SmithCHAnsteyAVBarkerJNBritish Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009Br J Dermatol20091615987101919857207
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug AdministrationHighlights of prescribing information [updated 2013 Jan 3]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125261s091lbl.pdf/Accessed March 1, 2014
   Google Scholar
• KoskinasJTampakiMDoumbaPPRallisEHepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patientBr J Dermatol2013168367968023121260
   PubMed Web of Science ®Google Scholar
• ChiuHYChenCHWuMSChengYPTsaiTFThe safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or CBr J Dermatol201316961295130323746170
   PubMed Web of Science ®Google Scholar
• ZeinNNEtanercept Study GroupEtanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled studyJ Hepatol200542331532215791697
   PubMed Web of Science ®Google Scholar
• NavarroRVilarrasaEHerranzPSafety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical settingBr J Dermatol2013168360961622985451
   PubMed Web of Science ®Google Scholar
• MotaparthiKStanisicVVan VoorheesASLebwohlMGHsuSFrom the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasisJ Am Acad Dermatol201470117818624220724
   PubMed Web of Science ®Google Scholar
• TsaiTFHoVSongMThe safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infectionBr J Dermatol201216751145115222803615
   PubMed Web of Science ®Google Scholar
• National Technic Steering Group of the Epidemiological Sampling Survey for TuberculosisReport on fourth national epidemiological sampling survey of tuberculosisChin J Tuberc Respir Dis2002251333
   Google Scholar
• ZhangGHuangSDuanQApplication of a hybrid model for predicting the incidence of tuberculosis in Hubei, ChinaPLoS One2013811e8096924223232
   PubMed Web of Science ®Google Scholar
• TsaiTFChiuHYSongMChanDA case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trialBr J Dermatol2013168244444622816505
   PubMed Web of Science ®Google Scholar
• Hermanns-LêTBerardescaEPiérardGELesuisseMPiérard-FranchimontCChallenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of diseaseJ Biomed Biotechnol2012201241376722927720
   PubMedGoogle Scholar
• YeildingNSzaparyPBrodmerkelCDevelopment of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives-an updateAnn N Y Acad Sci2012126311222823582
   PubMed Web of Science ®Google Scholar
• RustinMHLong-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current dataBrit J Dermatol2012167Suppl 331123082810
   PubMed Web of Science ®Google Scholar
• PiérardGEPiérard-FranchimontCSzepetiukGPaquetPQuatresoozPThe therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbiditiesExpert Opin Biol Ther20101081197120820560729
   PubMed Web of Science ®Google Scholar
• WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med CareJun1992306473483
   Google Scholar
• GospodarevskayaEPicotJCooperKLovemanETakedaAUstekinumab for the treatment of moderate to severe psoriasisHealth Technol Assess200913Suppl 3616619846031
   PubMed Web of Science ®Google Scholar
• TsaiTFSongMShenYKUstekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trialJ Drugs Dermatol201211894394922859239
   PubMed Web of Science ®Google Scholar
• StaidleJPDabadeTSFeldmanSRA pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiencyExpert Opin Pharmacother201112132041205421736530
   PubMed Web of Science ®Google Scholar